BriaCell Therapeutics Corp.BCT.TO

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · briacell.com

BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing targeted cellular immunotherapies for cancer treatment. Its lead program, Bria-IMT™, is in a pivotal Phase 3 clinical trial for metastatic breast cancer, while Bria-OTS™ is a personalized off-the-shelf immunotherapy designed to match patients' HLA types. The company also holds a license from the University of Maryland to develop soluble CD80 as a biologic cancer treatment.

Key ratios

ROA

-90.8%TTM

2025 -123.6%2024 -126.1%2023 -41.7%

ROE

-175.3%TTM

2025 -362.6%2023 -619.8%

Recent news

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study 2026-09-14 · GlobeNewswire BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+ 2026-08-24 · GlobeNewswire BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer 2026-08-05 · GlobeNewswire BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer 2026-07-16 · GlobeNewswire BriaCell Therapeutics Announces Closing of Offering 2026-06-02 · GlobeNewswire BriaCell Presents Positive Clinical Data at ASCO 2026 2026-06-01 · BioSpace

Track BCT.TO in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer